Document:

<PAGE>
                                                                    Exhibit 10.8

                                                Confidential Treatment Requested

(QUATRX LOGO)

QUATRx Pharmaceuticals Company
Chris I. Nicholas
5430 Data Court, Suite 300
Ann Arbor, MI 48108
(734) 9134900 * fax (134) 913.0743
www.quatrx.com - email cnicholas@quartx.com

CONFIDENTIAL

November 8, 2004

Deltanoid Pharmaceuticals, Inc.
645 Science Drive,
Madison, Wisconsin, 53711

     RE: Deltanoid-QuatRx Agreement

Dear Linda

As you know, over the past several months, we have discussed potential
amendments and updates to the Exclusive License Agreement between Deltanoid
Pharmaceuticals, Inc. and QuatRx Pharmaceuticals Company dated November 7, 2001
(the "Deltanoid-QuatRx License"). While we have discussed making certain changes
in the future, we at QuatRx would appreciate implementing 2 important agreed
changes at this time as follows:

1) Amend the Deltanoid-QuatRx License to include the following patent filings
(and their patent progeny as spelled out in the intellectual property
definitions in the existing agreements) within the "Licensed Patents" under each
of these agreements: US Patent Serial Number **** and US publication
numbers **** and ****.

2) Amend the Deltanoid-QuatRx License to provide that QuatRx shall have the
right to exercise Deltanoid's rights under Section 10 of the Deltainoid License
Agreement between Wisconsin Alumni Research Foundation and Deltanoid
Pharmaceuticals, Inc. dated April 7, 2000 ("WARF-Deltanoid License") with
respect to infringement that would be competitive with any product licensed to
QuatRx in the field of use set forth in the Deltanoid-QuatRx License.

The consideration for these amendments is that QuatRx will pay the royalties on
the basis of the patent filings coverage as specified in the current
Deltanoid-QuatRx License, as if these patent filings had originally been
included among the Licensed Patents under that agreement, and other good and
valuable consideration in the form of QuatRx's ongoing efforts and investment
with respect to the vitamin D analog product candidate that it is developing.

To indicate that Deltanoid agrees to these amendments (with all of the
agreements listed above otherwise remaining in full force and effect), please
let me know by email and then print and

<PAGE>

return to me a copy of this note signed by an authorized representative of your
organization. I will also send you an original signature on behalf of QuatRx for
your records.

We at QuatRx value highly our ongoing positive relationship with you and thank
you for prompt assistance with this mater.

Yours sincerely,

/s/ C. Nicholas
-------------------------------------

Accepted and agreed:

Deltanoid Pharmaceuticals, Inc.

By: /s/ Hector F. DeLuca
    ---------------------------------
Name: Hector F. DeLuca
Title: President & CEO Deltanoid
       Pharmaceuticals

Date: 11/10/04

                                        2<PAGE>

                                                                    Exhibit 10.9

                                                               Agreement 02-0207

                                   AGREEMENT
                                   ---------

     This Agreement ("Agreement") is made effective the 9th day of November,
2001, by and between Wisconsin Alumni Research Foundation (hereinafter called
"WARF"), a non-stock, nonprofit Wisconsin corporation, and Quatrx
Pharmaceuticals Company, (hereinafter called "Quatrx"), a corporation organized
and existing under the laws of the State of Delaware;

     WHEREAS, WARF has entered into that certain Deltanoid License Agreement
dated April 7, 2000 by and between WARF and Deltanoid Pharmaceuticals, Inc.
("Deltanoid"), a copy of which is attached hereto as Exhibit A (the "Deltanoid
Agreement");

     WHEREAS, under the terms of the Deltanoid Agreement, WARF licensed to
Deltanoid rights in certain compounds and inventions described in the Deltanoid
Agreement (the "Deltanoid Rights");

     WHEREAS, contemporaneous with the execution of this Agreement, Quatrx will
enter into an agreement with Deltanoid (a copy of which is attached hereto as
Exhibit B) pursuant to which Deltanoid shall sublicense to Quatrx certain
Deltanoid Rights (the "Deltanoid-Quatrx Agreement").

     WHEREAS, WARF and Quatrx desire to provide for the continued ability of
Quatrx to research, develop and commercialize product based on the Deltanoid
Rights even in the event that the Deltanoid Agreement is terminated.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set
forth below, the parties covenant and agree as follows:

Section 1. Consequence of Termination of Deltanoid Agreement.
           -------------------------------------------------

          In the event that (a) the Deltanoid Agreement is terminated for any
reason and (b) Quatrx has not breached the Deltanoid-Quatrx Agreement, then WARF
and Quatrx shall be deemed to have entered into an agreement identical to the
Deltanoid-Quatrx Agreement except that WARF shall be substituted for Deltanoid
in that agreement (such new agreement is hereinafter referred to as the "New
WARF-Quatrx Agreement"). In the event that WARF is prohibited by any applicable
law, rule or regulation from entering into the New WARF-Quatrx Agreement, or
WARF'S entering into such New WARF-Quatrx Agreement would adversely affect its
non-profit status, then the parties agree to enter into an agreement (the
"Modified New WARF-Quatrx Agreement") whereby (w) WARF shall license to Quatrx
the Deltanoid Rights licensed to Quatrx in the Deltanoid-Quatrx Agreement,
(x) such new agreement shall require payment to WARF of a royalty on net sales
of products based on the Deltanoid Rights which royalty is ****** that set forth
in the Deltanoid-Quatrx Agreement, (y) such new agreement shall require the
payment to WARF of other fees and milestones ****** those set forth in the
Deltanoid-Quatrx Agreement (less the amount of any such fees already paid by
Quatrx to Deltanoid) and (z) all other economic terms of such agreement shall
be the same as set forth in the Deltanoid-Quatrx Agreement.

Section 2. Cooperation.
           -----------

     In the event that a New WARF-Quatrx Agreement or a Modified New WARF-Quatrx
Agreement is entered into by the parties, WARF and Quatrx hereby agree to
cooperate in the exchange of such information, including, without limitation,
pre-clinical and clinical research reports, patent applications and related
prosecution histories, and other documentation as shall be necessary to permit
the continued and uninterrupted research, development and commercialization of
products based on the Deltanoid Rights to the extent such information is in the
possession of WARF and Quatrx respectively.

<PAGE>

Section 3.     Miscellaneous.

          This Agreement shall be governed by and construed in all respects in
accordance with the laws of the State of Wisconsin. If any provisions of this
Agreement are or shall come into conflict with the laws or regulations of any
jurisdiction or any governmental entity having jurisdiction over the parties
or this Agreement, those provisions shall be deemed automatically deleted, if
such deletion is allowed by relevant law, and the remaining terms and
conditions of this Agreement shall remain in full force and effect. If such a
deletion is not so allowed or if such a deletion leaves terms thereby made
clearly illogical or inappropriate in effect, the parties agree to substitute
new terms as similar in effect to the present terms of this Agreement as may be
allowed under the applicable laws and regulations. The parties hereto are
independent contractors and not joint venturers or partners.

Section 4.     Notices.

          Any notice required to be given pursuant to the provisions of this
Agreement shall be in writing and shall be deemed to have been given at the
earlier of the time when actually received as a consequence of any effective
method of delivery, including but not limited to hand delivery, transmission by
telecopier, or delivery by a professional courier service or the time when sent
by certified or registered mail or a nationally recognized overnight delivery
service addressed to the party for whom intended at the address below or at such
changed address as the party shall have specified by written notice, provided
that any notice of change of address shall be effective only upon actual
receipt.

          (a)  Wisconsin Alumni Research Foundation
               Attn: Managing Director
               614 Walnut Street
               Madison, Wisconsin 53705

          (b)  Quatrx Pharmaceuticals, Inc.
               5430 Data Court, Suite 300
               Ann Arbor, MI 48108
               Attention: CEO
               Telephone: 734-913-0743
               Telecopy:  734-913-9900

Section 5.     Integration.

          This Agreement constitutes the full understanding between the parties
with reference to the subject matter hereof, and no statements or agreements by
or between the parties, whether orally or in writing, except as provided for
elsewhere in this Section 5, made prior to or at the signing hereof, shall vary
or modify the written terms of this Agreement. Neither party shall claim any
amendment, modification, or release from any provisions of this Agreement by
mutual agreement, acknowledgment, or otherwise, unless such mutual agreement is
in writing, signed by the other party, and specifically states that it is an
amendment to this Agreement.

Section 6.     Authority.

          The persons signing on behalf of WARF and Quatrx hereby warrant and
represent that they have authority to execute this Agreement on behalf of the
party for whom they have signed and that each such contracting party is
authorized to enter into this Agreement. The execution, delivery and
performance of this Agreement by such Party does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a Party
or by which it is bound, nor violate any law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.

<PAGE>
Section 7.  Counterparts.

     This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original and all of which together shall constitute
one and the same instrument.

     IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement
on the dates indicated below.

 WISCONSIN ALUMNI RESEARCH FOUNDATION

By: /s/ Carl E. Gulbrandsen                  Date: 11/14, 2001
   --------------------------------------          --------------------
   Carl E. Gulbrandsen, Managing Director

 QUATRX PHARMACEUTICALS COMPANY

By: /s/ ROBERT L. ZERBE                      Date: 11/9, 2001
   --------------------------------------          --------------------
Name and Office: ROBERT L. ZERBE
                -------------------------------------------------------
  CHIEF EXECUTIVE OFFICER
--------------------------------------
Reviewed by WARF's Attorney:

/s/ Elizabeth L.R. Donley                          11/14, 2001
-----------------------------------------          --------------------
Elizabeth L.R. Donley, Esq.

(WARF's attorney shall not be deemed a signatory to this Agreement.)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]